ClinicalTrials.Veeva

Menu

Labetalol to Prevent Hypertension and Tachycardia During Fiberoptic Bronchoscopy

Clalit Health Services logo

Clalit Health Services

Status and phase

Completed
Phase 4

Conditions

Bronchoscopy

Treatments

Drug: Labetalol 10mg iv

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

Passing a bronchoscope through the airways frequently causes a stress response even though patients are sedated. This stress response is usually an increase in pulse and blood pressure, which may have undesirable effects on the heart and circulation.

We plan to give patients labetalol (a beta blocker which reduces pulse and blood pressure) in addition to normal sedation, to patients undergoing bronchoscopy in our department.

Enrollment

72 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • All patients over 18 years old undergo fiberoptic bronchoscopy in our unit

Exclusion criteria

  • inability or refusal to give informed consent
  • bronchoscopy through an artificial airway
  • intolerance or allergy to the study drug
  • bradycardia (HR<60/min) or hypotension (systolic BP <100) at screening
  • pregnancy,
  • concomitant treatment with diltiazem or verapamil
  • intention to use propofol as the sedative agent for bronchoscopy.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems